Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients

M Kanbay, D Siriopol, M Saglam, YG Kurt… - The Journal of …, 2014 - academic.oup.com
Background: The chronic kidney disease (CKD)-mineral and bone disorder (MBD)
syndrome is an important contributor to the CKD-associated cardiovascular disease and …
被引用次数：136 相关文章

Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients

M Kanbay, D Siriopol, M Saglam… - The Journal of …, 2014 - pubmed.ncbi.nlm.nih.gov
Background The chronic kidney disease (CKD)-mineral and bone disorder (MBD) syndrome
is an important contributor to the CKD-associated cardiovascular disease and high mortality …

Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.

M Kanbay, D Siriopol, M Saglam, YG Kurt… - The Journal of …, 2014 - europepmc.org
Background The chronic kidney disease (CKD)-mineral and bone disorder (MBD) syndrome
is an important contributor to the CKD-associated cardiovascular disease and high mortality …

[引用][C] Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients

M Kanbay, D Siriopol, M Saglam, YG Kurt… - The Journal of Clinical …, 2014 - cir.nii.ac.jp
Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
[PDF] researchgate.net

[PDF][PDF] Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients

M Kanbay, D Siriopol, M Saglam, YG Kurt, M Gok… - 2014 - researchgate.net
Background. The chronic kidney disease–mineral and bone disorder (CKD–MBD) syndrome
is an important contributor to the CKD-associated cardiovascular disease and high mortality …
[PDF] academia.edu

[PDF][PDF] Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients

M Kanbay, D Siriopol, M Saglam, YG Kurt, M Gok… - 2014 - academia.edu
Background. The chronic kidney disease–mineral and bone disorder (CKD–MBD) syndrome
is an important contributor to the CKD-associated cardiovascular disease and high mortality …
[PDF] academia.edu

[PDF][PDF] Serum sclerostin and adverse outcomes in non-dialyzed chronic kidney disease patients

M Kanbay, D Siriopol, M Saglam, YG Kurt, M Gok… - 2014 - academia.edu
Background. The chronic kidney disease–mineral and bone disorder (CKD–MBD) syndrome
is an important contributor to the CKD-associated cardiovascular disease and high mortality …

[引用][C] Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients

M Kanbay, D Siriopol, M Saglam, YG Kurt, M Gok… - J Clin Endocrinol Metab, 2014